Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre for Addiction and Mental Health
This is an open-label pilot randomized, wait-list controlled trial evaluating A-EMDR for the treatment of PTSD in patients with SUD for four weeks with a follow up at week eight. Primary outcomes will be measured at the end of the study (week 4) for both groups and at follow up (week 8) for the A-EMDR group.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18-years old or older
Fluent in English
Diagnosed with PTSD by the PTSD Checklist for DSM-5 (PCL-5 past month version score \>32)
Diagnosed with past-year substance use disorder other than caffeine by structured clinical interview for DSM-5 (SCID-5)
Agrees not to participate in other treatments during the study duration (e.g., mindfulness, yoga, biofeedback, self-hypnosis or tai chi) except individuals who have been already on continuous therapies for at least three months
You may not be if
Diagnosis of a severe or unstable mental illness that precludes safe participation in the study by a healthcare practitioner such as acute psychosis or mania diagnosed by a healthcare practitioner
Current suicidality risk as indicated during the conduct of the Columbia Suicide Severity Rating Scale (C-SSRS) (21) with concurrence after a study physician's evaluation if the response to C-SSRS questions 1 or 2 is "yes"
Clareo Health | Efficacy of an EMDR App for PTSD and SUD
